Domain III of the envelope protein as a dengue vaccine target

Expert Review of Vaccines

Volumn 9, Issue 2, 2010, Pages 137-147

  Guzman, Maria G ^a   Hermida, Lisset ^b   Bernardo, Lidice ^a   Ramirez, Rosa ^a   Guillén, Gerardo ^b  

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Cuba; Dengue; Domain III; Envelope; Neisseria meningitidis; P64k protein; Vaccine

Indexed keywords

ANTIBODY; CHIMERIC PROTEIN; DENGUE VACCINE; ENVELOPE PROTEIN; HYBRID PROTEIN; LPDA PROTEIN, NEISSERIA MENINGITIDIS; NEUTRALIZING ANTIBODY; OUTER MEMBRANE PROTEIN; SUBUNIT VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

COST; DENGUE VIRUS; ESCHERICHIA COLI; HUMAN; IMMUNE RESPONSE; IMMUNITY; MONKEY; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; VIRUS INFECTION; ANIMAL; DENGUE; GENETICS; HAPLORHINI; IMMUNOLOGY; PROTEIN TERTIARY STRUCTURE; VIRUS ATTACHMENT;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BACTERIAL OUTER MEMBRANE PROTEINS; DENGUE; DENGUE VACCINES; HAPLORHINI; HUMANS; MICE; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; VACCINES, SUBUNIT; VIRAL ENVELOPE PROTEINS; VIRUS ATTACHMENT;

EID: 77950350548     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.139     Document Type: Review

References (102)

1. Guzman MG, Kouri G. Dengue: an update. Lancet Infect. Dis. 2(1), 33-42 (2002). (Pubitemid 36109304)
2. Kroeger A, Nathan MB. Dengue: setting the global research agenda. Lancet 368(9554), 2193-2195 (2006). (Pubitemid 44958999)
3. Nathan MB, Dayal-Drager R. Recent epidemiological trends, the global strategy and public health advances in dengue. TDR/Scientifc Working Group. Geneva, Switzerland, 1-5 October 2006.
4. Guzman MG, Vazquez S, Kouri G. Dengue: where are we today? Malaysian J. Med. Sciences 16(3), 5-12 (2009).
5. Kuno G. Research on dengue and dengue-like illness in East Asia and the Western Pacifc during the frst half of the 20th Century. Rev. Med. Virol. 17(5), 327-341 (2007). (Pubitemid 47425870)
6. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st Century. Trends Microbiol. 10(2), 100-103 (2002).
7. PAHO. Dengue and dengue hemorrhagic fever in the Americas: guidelines for prevention and control. Scientifc publication no.548. PAHO, Washington, DC, USA (1994).
8. Kouri GP, Guzman MG, Bravo JR. Why dengue haemorrhagic fever in Cuba? 2. An integral ana lysis. Trans. R. Soc. Trop. Med. Hyg 81(5), 821-823 (1987).
9. Guzman MG, Kouri G. Dengue haemorrhagic fever integral hypothesis: confrming observations, 1987-2007. Trans. R. Soc. Trop. Med. Hyg. 102(6), 522-523 (2008).
10. Bravo JR, Guzman MG, Kouri GP. Why dengue haemorrhagic fever in Cuba? 1. Individual risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). Trans. R. Soc. Trop. Med. Hyg. 81(5), 816-820 (1987).
11. Guzman MG, Kouri G, Bravo J et al. Effect of age on outcome of secondary dengue 2 infections. Int. J. Infect. Dis. 6(2), 118-124 (2002). (Pubitemid 34793060)
12. Halstead SB. Dengue. Lancet 370(9599), 1644-1652 (2007).
13. Gonzalez D, Castro OE, Kouri G et al. Classical dengue hemorrhagic fever resulting from two dengue infections spaced 20 years or more apart: Havana, dengue 3 epidemic, 2001-2002. Int. J. Infect. Dis. 9(5), 280-285 (2005).
14. Sierra B, García G, Pérez AB et al. Ethnicity and difference in dengue virus-specifc memory T cell responses in Cuban individuals. Viral Immunol. 19(4), 662-668 (2006). (Pubitemid 46068059)
15. Kou Z, Quinn M, Chen H et al. Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J. Med. Virol. 80(1), 134-146 (2008). (Pubitemid 350220099)
16. Rodrigo W W, Jin X, Blackley SD, Rose RC, Schlesinger JJ. Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcg RIA (CD64) or FcgRIIA (CD32). J. Virol. 80(20), 10128-10138 (2006). (Pubitemid 44522606)
17. Kontny U, Kurane I, Ennis FA. g interferon augments Fc g receptor-mediated dengue virus infection of human monocytic cells. J. Virol. 62(11), 3928-3933 (1988).
18. Littaua R, Kurane I, Ennis FA. Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J. Immunol. 144(8), 3183-3186 (1990). (Pubitemid 20149498)
19. Halstead SB. Observations related to pathogenesis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J. Biol. Med. 42(5), 350-362 (1970).
20. Halstead SB, Lan NT, Myint TT et al. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg. Infect. Dis. 8(12), 1474-1479 (2002).
21. Libraty DH, Endy TP, Houng HS et al. Differing infuences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J. Infect. Dis. 185(9), 1213-1221 (2002).
22. Vaughn DW, Green S, Kalayanarooj S et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181(1), 2-9 (2000). (Pubitemid 30049026)
23. Mongkolsapaya J, Duangchinda T, Dejnirattisai W et al. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J. Immunol. 176(6), 3821-3829 (2006). (Pubitemid 43364031)
24. Clyde K, Kyle JL, Harris E. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J. Virol. 80(23), 11418-11431 (2006). (Pubitemid 44788858)
25. Pang T, Cardosa MJ, Guzman MG. Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). Immunol. Cell Biol. 85(1), 43-45 (2007). (Pubitemid 46067320)
26. Hombach J. Vaccines against dengue: a review of current candidate vaccines at advanced development stages. Rev. Panam. Salud. Publica 21(4), 254-260 (2007). (Pubitemid 47147601)
27. Guzman MG, Mune M, Kouri G. Dengue vaccine: priorities and progress. Expert Rev. Anti Infect. Ther. 2(6), 895-911 (2004). (Pubitemid 39591922)
28. Barrett AD, Hombach J. Opportunities in the development of dengue vaccines. TDR/Scientifc Working Group. WHO, Geneva, Switzerland, 1-5 October 2006.
29. Alvarez M, Rodriguez-Roche R, Bernardo L et al. Dengue hemorrhagic fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. Am. J. Trop. Med. Hyg. 75(6), 1113-1117 (2006). (Pubitemid 351627493)
30. Hombach J, Cardosa MJ, Sabchareon A, Vaughn DW, Barrett AD. Scientifc consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005. Vaccine 25(21), 4130-4139 (2007).
31. Guzman MG, Kouri G, Valdes L et al. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev. Panam. Salud. Publica 11(4), 223-227 (2002). (Pubitemid 34555771)
32. Blaney JE Jr, Matro JM, Murphy BR, Whitehead SS. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J. Virol. 79(9), 5516-5528 (2005).
33. Brandler S, Tangy F. Recombinant vector derived from live attenuated measles virus: potential for favivirus vaccines. Comp. Immunol. Microbiol. Infect Dis. 31(2-3), 271-291 (2008). (Pubitemid 351315119)
34. Guirakhoo F, Kitchener S, Morrison D et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum. Vaccin. 2(2), 60-67 (2006). (Pubitemid 43927159)
35. Putnak RJ, Coller BA, Voss G et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 23(35), 4442-4452 (2005). (Pubitemid 40991230)
36. Sun W, Cunningham D, Wasserman SS et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in favivirus-naive adults. Hum. Vaccin. 5(1), 33-40 (2009).
37. Velzing J, Groen J, Drouet MT et al. Induction of protective immunity against dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines. Vaccine 17(11-12), 1312-1320 (1999). (Pubitemid 29138797)
38. Apt D, Raviprakash K, Brinkman A et al. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen. Vaccine 24(3), 335-344 (2006). (Pubitemid 41790437)
39. Blair PJ, Kochel TJ, Raviprakash K et al. Evaluation of immunity and protective effcacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys. Vaccine 24(9), 1427-1432 (2006). (Pubitemid 43222054)
40. Sabchareon A, Lang J, Chanthavanich P et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am. J. Trop. Med. Hyg 66(3), 264-272 (2002). (Pubitemid 34756095)
41. Simmons M, Porter KR, Hayes CG, Vaughn DW, Putnak R. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J. Virol. 80(19), 9577-9585 (2006). (Pubitemid 44435632)
42. Zhang W, Chipman PR, Corver J et al. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat. Struct. Biol. 10(11), 907-912 (2003). (Pubitemid 37386099)
43. Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. Nature 427(6972), 313-319 (2004). (Pubitemid 38133652)
44. Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most effcient blockers of virus adsorption to Vero cells. J. Virol. 75(16), 7769-7773 (2001).
45. Hung JJ, Hsieh MT, Young MJ et al. An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specifc binding to mosquito but not mammalian cells. J. Virol. 78(1), 378-388 (2004).
46. Chen Y, Maguire T, Hileman RE et al. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3(8), 866-871 (1997). (Pubitemid 27353446)
47. Huerta V, Chinea G, Fleitas N et al. Characterization of the interaction of domain III of the envelope protein of dengue virus with putative receptors from CHO cells. Virus Res. 137(2), 225-234 (2008).
48. Roehrig JT, Volpe KE, Squires J et al. Contribution of disulfde bridging to epitope expression of the dengue type 2 virus envelope glycoprotein. J. Virol. 78(5), 2648-2652 (2004). (Pubitemid 38228966)
49. Kuhn RJ, Zhang W, Rossmann MG et al. Structure of dengue virus: implications for favivirus organization, maturation, and fusion. Cell 108(5), 717-725 (2002). (Pubitemid 34241430)
50. Chin JF, Chu JJ, Ng ML. The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microbes Infect. 9(1), 1-6 (2007).
51. Roehrig JT. Antigenic structure of favivirus proteins. Adv. Virus Res. 59, 141-175 (2003).
52. Lok SM, Ng ML, Aaskov J. Amino acid and phenotypic changes in dengue 2 virus associated with escape from neutralisation by IgM antibody J. Med. Virol. 65(2), 315-323 (2001).
53. Lok SM, Kostyuchenko V, Nybakken GE et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 15(3), 312-317 (2008). (Pubitemid 351654038)
54. Gromowski GD, Barrett AD. Characterization of an antigenic site that contains a dominant, type-specifc neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366(2), 349-360 (2007).
55. Hiramatsu K, Tadano M, Men R, Lai CJ. Mutational ana lysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence. Virology 224(2), 437-445 (1996). (Pubitemid 26364491)
56. Lin B, Parrish CR, Murray JM, Wright PJ. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. Virology 202(2), 885-890 (1994). (Pubitemid 24254902)
57. Zulueta A, Martin J, Hermida L et al. Amino acid changes in the recombinant Dengue 3 envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res. 121(1), 65-73 (2006). (Pubitemid 44040901)
58. Gromowski GD, Barrett ND, Barrett AD. Characterization of dengue virus complex-specifc neutralizing epitopes on envelope protein domain III of dengue 2 virus. J. Virol. 82(17), 8828-8837 (2008).
59. Añez G, Men R, Eckels KH, Lai CJ. Passage of dengue virus type 4 vaccine candidates in fetal rhesus lung cells selects heparin-sensitive variants that result in loss of infectivity and immunogenicity in rhesus macaques. J. Virol. 83(20), 10384-10394 (2009).
60. Megret F, Hugnot JP, Falconar A et al. Use of recombinant fusion proteins and monoclonal antibodies to defne linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. Virology 187(2), 480-491 (1992).
61. Roehrig JT, Bolin RA, Kelly RG. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246(2), 317-328 (1998).
62. Simmons M, Nelson WM, Wu SJ, Hayes CG. Evaluation of the protective effcacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am. J. Trop. Med. Hyg. 58(5), 655-662 (1998). (Pubitemid 28237267)
63. Simmons M, Murphy GS, Hayes CG. Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am. J. Trop. Med. Hyg. 65(2), 159-161 (2001). (Pubitemid 32744223)
64. Khanam S, Etemad B, Khanna N, Swaminathan S. Induction of neutralizing antibodies specifc to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes. Am. J. Trop. Med. Hyg. 74(2), 266-277 (2006). (Pubitemid 46774340)
65. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392(1), 103-113 (2009).
66. Crill WD, Hughes HR, Delorey MJ, Chang GJ. Humoral immune responses of dengue fever patients using epitope-specifc serotype-2 virus-like particle antigens. PLoS One 4(4), e4991 (2009).
67. Fonseca BAL, Khoshnood K, Shope RE, Mason PW. Flavivirus type-specifc antigens produced from fusions of a portion of the E protein gene with the Escherichia coli TRPE gene. Am. J. Trop. Med. Hyg. 44(5), 500-508 (1991).
68. Srivastava AK, Putnak JR, Warren RL, Hoke CH Jr. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine 13(13), 1251-1258 (1995).
69. Simmons M, Murphy GS, Kochel T, Raviprakash K, Hayes CG. Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine. Am. J. Trop. Med. Hyg. 65(5), 420-426 (2001). (Pubitemid 33134572)
70. Jaiswal S, Khanna N, Swaminathan S. High-level expression and one-step purifcation of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli. Protein Expr. Purif. 33(1), 80-91 (2004). (Pubitemid 38069818)
71. Etemad B, Batra G, Raut R et al. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Am. J. Trop. Med. Hyg. 79(3), 353-363 (2008).
72. Khanam S, Pilankatta R, Khanna N, Swaminathan S. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine 27(43), 6011-6021 (2009).
73. Chen S, Yu M, Jiang T et al. Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein. DNA Cell Biol. 26(6), 361-367 (2007). (Pubitemid 46981691)
74. Zhang ZS, Yan YS, Weng YW et al. High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice. J. Virol. Methods 143(2), 125-131 (2007). (Pubitemid 46963382)
75. Babu JP, Pattnaik P, Gupta N et al. Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice. Vaccine 26(36), 4655-4663 (2008).
76. Pattnaik P, Babu JP, Verma SK, Tak V, Rao PV. Bacterially expressed and refolded envelope protein (domain III) of dengue virus type-4 binds heparan sulfate. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 846(1-2), 184-194 (2007). (Pubitemid 46149513)
77. Leng CH, Liu SJ, Tsai JP et al. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect. 11(2), 288-295 (2009).
78. Mota J, Acosta M, Argotte R et al. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 23(26), 3469-3476 (2005). (Pubitemid 40517122)
79. Khanam S, Khanna N, Swaminathan S. Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors. Vaccine 24(42-43), 6513-6525 (2006). (Pubitemid 44511859)
80. Khanam S, Rajendra P, Khanna N, Swaminathan S. An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes. BMC Biotechnol. 7, 10 (2007). (Pubitemid 46359486)
81. Brandler S, Lucas-Hourani M, Moris A et al. Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specifc neutralizing antibodies to dengue virus. PLoS Negl. Trop. Dis. 1(3), e96 (2007). (Pubitemid 352024640)
82. Catteau A, Kalinina O, Wagner MC et al. Dengue virus M protein contains a proapoptotic sequence referred to as ApoptoM. J. Gen. Virol. 84(Pt 10), 2781-2793 (2003). (Pubitemid 37220257)
83. Saejung W, Fujiyama K, Takasaki T et al. Production of dengue 2 envelope domain III in plant using TMV-based vector system. Vaccine 25(36), 6646-6654 (2007). (Pubitemid 47224986)
84. Sim AC, Lin W, Tan GK et al. Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen. Vaccine 26(9), 1145-1154 (2008).
85. González S, Álvarez A, Caballero E. P64k meningococcal protein as immunological carrier for weak immunogens. Scand. J. Immunol. 52(2), 113-116 (2000).
86. Perez A, Dickinson F, Cinza Z et al. Safety and preliminary immunogenicity of the recombinant outer membrane protein P64k of Neisseria meningitidis in human volunteers. Biotechnol. Appl. Biochem. 34(Pt 2), 121-125 (2001). (Pubitemid 32977943)
87. Hermida L, Rodriguez R, Lazo L et al. A dengue-2 envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J. Virol. Methods 115(1), 41-49 (2004). (Pubitemid 37500961)
88. Hermida L, Rodriguez R, Lazo L et al. A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnol. Appl. Biochem. 39(Pt 1), 107-114 (2004). (Pubitemid 38200939)
89. Zulueta A, Hermida L, Lazo L et al. The fusion site of envelope fragments from each serotype of Dengue virus in the P64k protein, infuence some parameters of the resulting chimeric constructs. Biochem. Biophys. Res. Commun. 308(3), 619-626 (2003). (Pubitemid 36945538)
90. Hermida L, Bernardo L, Martin J et al. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24(16), 3165-3171 (2006).
91. Lazo L, Zulueta A, Hermida L et al. Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice. Biotechnol. Appl. Biochem. 52(Pt 4), 265-271 (2009).
92. Bernardo L, Izquierdo A, Alvarez M et al. Immunogenicity and protective effcacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res. 80(2), 194-199 (2008).
93. Valdes I, Hermida L, Martin J et al. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis. Vaccine 27(7), 995-1001 (2009).
94. Izquierdo A, Bernardo L, Martin J et al. Serotype-specifcity of recombinant fusion proteins containing domain III of dengue virus. Virus Res. 138(1-2), 135-138 (2008).
95. Bernardo L, Hermida L, Martin J et al. Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins. Arch. Virol. 153(5), 849-854 (2008).
96. Valdés I, Hermida L, Gil L et al. Heterologous prime-boost strategy in nonhuman primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use. Int. J. Infect. Dis. DOI: 10.1016/j.ijid.2009.06.017 (2009) (Epub ahead of print).
97. Sabchareon A, Lang J, Chanthavanich P et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in fve-to twelve-year-old Thai children. Pediatr. Infect. Dis. J. 23(2), 99-109 (2004). (Pubitemid 38222779)
98. Simasathien S, Thomas SJ, Watanaveeradej V et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in favivirus naive children. Am. J. Trop. Med. Hyg. 78(3), 426-433 (2008). (Pubitemid 351845193)
99. Guy B, Nougarede N, Begue S et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or favivirus-primed subjects. Vaccine 26(45), 5712-5721 (2008).
100. Lazo L, Hermida L, Zulueta A et al A recombinant capsid protein from dengue-2 induces protection in mice against homologous virus. Vaccine 25 (6), 1064-1070 (2007). (Pubitemid 44940828)
101. + cells against viral encephalitis in mice. Int. Immunol. 21(10), 1175-1183 (2009).
102. Valdés I, Bernardo L, Gil L et al. A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology 394(2), 249-258 (2009).